S1RA [878141-96-9]
Referência HY-18099-5mg
Tamanho : 5mg
Marca : MedChemExpress
Description |
S1RA (E-52862) is a highly selective σ1 receptor (σ1R) antagonist with Kis of 17 nM and 23.5 nM for human σ1R and guinea pig σ1R, respectively. S1RA has Moderate antagonistic activity for human 5-HT2B receptor (Ki= 328 nM). S1RA has antinociceptive effects in neuropathic pain models. S1RA prevents mechanical and cold hypersensitivity in Oxaliplatin (HY-17371)-treated mice[1][2]. |
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1][3] |
|
|||||||||||||||
Cellular Effect |
|
|||||||||||||||
In Vitro |
S1RA (E-52862; 100 µM; 4 h) inhibit intracellular calcium responses in TRPA1 expressing HEK293 cells[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
|||||||||||||||
In Vivo |
S1RA (E-52862; 40 mg/kg; IP; single dose) produces a substantial reduction in pain-related responses to intradermal Allylisothiocyanate (AITC) in WT mice[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
|
|||||||||||||||
Masse moléculaire |
337.42 |
|||||||||||||||
Formule |
C20H23N3O2 |
|||||||||||||||
CAS No. | ||||||||||||||||
Appearance |
Solid |
|||||||||||||||
Color |
Off-white to yellow |
|||||||||||||||
SMILES |
CC1=CC(OCCN2CCOCC2)=NN1C3=CC(C=CC=C4)=C4C=C3 |
|||||||||||||||
Livraison | Room temperature in continental US; may vary elsewhere. |
|||||||||||||||
Stockage |
|
|||||||||||||||
Solvant et solubilité |
In Vitro:
1M HCl : 50 mg/mL (148.18 mM; ultrasonic and adjust pH to 1 with HCl) DMSO : 33.33 mg/mL (98.78 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
|
|||||||||||||||
Pureté et documentation | ||||||||||||||||
Références |
|